CloudBackend Raises €6.6 million Led by Carl-Henric Svanberg’s Family Office

Funding will expand access to CloudBackend’s AI cloud infrastructure helping creators scale AI-built applications from prototype into profitable businesses

LINKÖPING, Sweden, Nov. 18, 2026 — CloudBackend AB, the AI cloud infrastructure company helping creators turn vibe-coded prototypes into production-grade business applications, announced that it has raised €6.6 million in a financing round led by the family office of Carl-Henric Svanberg, who most recently chaired the Swedish Government’s AI Commission. Existing investor M2 Asset Management also increased its stake in the company.

“AI has made it much easier to build the first version of an application. The challenge comes when customers sign in and expect the service to be secure, reliable and available every day,” said Daniel Arthursson, founder and CEO of CloudBackend. “We’re building the AI cloud infrastructure that helps creators make that leap without extensive technical knowledge. It’s a new type of infrastructure designed for applications built with AI.”

AI can quickly turn an idea into a working prototype. Turning that prototype into a business requires security, scalability, reliable operations and effective customer support. Creators also need built-in monetisation and insights to guide decisions on product design, pricing and target markets. CloudBackend brings these capabilities together in a single integrated platform, designed to be simple enough for an individual creator to operate while supporting the needs of a growing team.

“AI is making it easier to build applications, but turning them into production-grade solutions for businesses is a different challenge. We see a growing need for infrastructure that helps businesses to operate securely, serve customers reliably and to expand their offerings. Daniel and his team have the experience and expertise to address that need, which is why we chose to lead this round,” said Hans Lindroth, CEO of the Svanberg family office.

The company will use the new capital to broaden access to its platform for creators building with AI and to develop integrations with generative AI development platforms and large language models. Selected creators will begin onboarding to the CloudBackend beta on November 24.

“We backed this team before, and we are backing them again. Building the platform that quickly enables making a scalable business out of AI-generated apps and services is the next natural step for vibe coding,” said Jakob Mörndal, CEO of M2 Asset Management and a member of CloudBackend’s board.

Media contacts:
[email protected]

Doug Hunter
Director, SoContent Communications
[email protected]
+44(0)7510381111

About CloudBackend
CloudBackend is the AI cloud infrastructure company for creators making AI-built applications into a scalable monetisable business. Its operations platform combines the Singularity Database with user authentication, subscriptions, payments, statistics, support, CRM, i.e. everything needed to operate a SaaS business. Founded in 2018, CloudBackend is headquartered in Linköping, Sweden. Learn more at cloudbackend.com.

About the Svanberg Family Office
The Svanberg family office invests across public and private markets. Carl-Henric Svanberg previously served as President and CEO of Ericsson, Chairman of BP and AB Volvo, and Chairman of the Swedish Government’s AI Commission.

About M2 Asset Management
M2 Asset Management AB is a Stockholm-based investment company and family office focused on long-term, active ownership. Its major holdings include Corem Property Group, Wästbygg Gruppen and Devyser Diagnostics.

About Daniel Arthursson
A serial entrepreneur in deep tech, building on previous experiences founding companies and well-known brands like CloudMe.com, iCloud.com (acquired by Apple), CloudTop.com, and XIOS3.com.

About Hans Lindroth
Chief Executive Officer at CH Svanberg AB. He has served on more than 60 boards of four continents.

About Jakob Mörndal
Jakob Mörndal is CEO of M2 Asset Management AB. He serves on the boards of several companies.

SOURCE CloudBackend AB

Hone Health Raises $228M to Expand Physician-Led Longevity Care for Men and Women

The funding, led by MarcyPen Capital Partners, will fuel new clinical pathways and the AI-enabled technology that turns patient data into proactive physician-directed care

NEW YORK, Nov. 18, 2026 — Hone Health, a physician-led longevity platform that helps people design a personalized plan for their health and longevity, today announced it has raised $228M in financing. The round was led by MarcyPen Capital Partners, a first-of-its-kind global investment platform that provides strategic capital to growth stage consumer businesses that create, move, and lead culture. MarcyPen has been a partner to Hone for over two years, having led the company’s Series A financing, a role that had not previously been disclosed, and continuing to support the company through follow-on investments.

The Series A extension included additional participation from Pentland Ventures, Kinship Ventures co-founded by Gwyneth Paltrow and Moj Mohdara, Hanwha, Gannet Capital, humbition, and Comma Capital, and ID Ventures. The investment is structured as $28M in equity as a Series A financing and $200M in growth financing from General Catalyst’s Customer Value Fund (CVF).

David Grutman has joined Hone Health as a strategic investor and advisor. Grutman has also brought a group of high-profile strategic investors, including Marcello Hernández, Nick Jonas, Joe Jonas, Kevin Jonas, Braxton Berrios, and Kelly Rowland, Jason Strauss and Noah Tepperberg. Additional investors include former NBA player Josh Childress, along with Quentin Dolan, Raj Gokal, Tushar Jain, Kyle Samani, Halle Tecco, and Zachary Gordan. The financing brings Hone’s total equity funding to $65 million. After years of reactionary purchasing, consumers have shifted their focus to proactive wellness. 89% of women want to be more proactive in managing their health, and in 2025, nutrition and personal care spending accounted for over 90% of consumer health sales, reflecting a more proactive approach to well-being.

“Today, consumers have almost limitless options when it comes to preventative health, but what people are looking for is the highest level of insight into their metrics, so that they can make more informed decisions about their health,” said Saad Alam, Co-Founder & CEO of Hone Health. “Hone combines comprehensive diagnostic testing, physician-led care, and AI-powered insights to deliver that level of understanding. This funding will allow us to extend that vision across new therapeutic categories and start building toward our ultimate vision: a research platform to accelerate health outcomes.”

Jay Brown, Co-Founder and Managing Partner at MarcyPen Capital Partners, said, “Saad and the team at Hone are proven business builders dedicated to making it easier for people to live better, healthier lives. We believe in their vision and are proud to deepen our partnership with them.”

Expanding the Infrastructure for Personalized Healthspan Medicine

Hone will use the investment to support five areas of expansion:

  • Broader Clinical Care: Launch and scale physician-led programs across metabolic health, PMOS, inflammation, and immunity, giving patients a more connected view of the factors influencing their health.
  • Advanced Diagnostics: Integrate additional diagnostic tools into longitudinal patient care, including full-body MRI, DEXA scans, coronary CT angiography, and gut microbiome analysis, while creating one of the most complete health datasets ever assembled.
  • Clinical Technology: Advance AI-enabled care and the tools that bring together lab results, health history, symptoms, medications, and longitudinal outcomes to help physicians personalize and adapt care – accelerating the buildout of the technology that turns biomarkers into personalized treatment plans.
  • Emerging Therapies: Launch a physician-supervised peptide program providing eligible patients with access to select peptide therapies where legally available and clinically appropriate.
  • Research & Trials: Accelerate the clinical trials infrastructure that allows Hone to understand what kinds of care are driving the best patient outcomes.

Introducing Hone Black

Finally, Hone will publicly launch Hone Black, its most comprehensive and personalized membership. The concierge longevity program has operated in stealth for the past year, serving a select group of high-profile patients.

Hone Black combines extensive diagnostics (1,600+ health markers) with ongoing medical care from a dedicated team of physicians responsible for whole-body care. Treatment options span prescription medications, supplements, peptides, and lifestyle guidance, as well as exosome and stem cell therapies.

“When I started goop, wellness was a niche conversation,” said Gwyneth Paltrow, founder and CEO of goop and co-founder of Kinship Ventures. “Today it’s one of the biggest categories in the world, and the next step is bringing real health and wellness to the masses, not just the few. Saad has built Hone to do exactly that, with serious science and at real scale. That’s why Kinship invested, and we could not be more excited about what’s ahead.”

“The next great health company will be built on data,” said Moj Mahdara, co-founder and managing partner of Kinship Ventures. “Hone has treated more than 200,000 patients and turned that into one of the largest hormone and metabolic datasets in the world, making its physicians smarter with every patient. Kinship is proud to stand alongside Saad as Hone scales.”

“People have never had more data about their own bodies and never less guidance on what to do with it,” said Omar Hatteea, Investment Manager at Pentland Ventures. “Hone closes that gap by pairing serious diagnostics with physicians who stay with a patient over years rather than appointments. That longitudinal relationship is the cornerstone of our Health OS thesis, and we are excited for what lies ahead for Hone.”

The financing follows Hone’s $33 million Series A, announced in January 2025, which supported the company’s expansion beyond hormone health optimization into broader longevity care. Since that round, Hone has launched a cardiovascular program that evaluates risk using advanced health markers and integrated Prenuvo whole-body MRI and BodySpec DEXA scans.

About Hone Health

Hone Health is a physician-led longevity platform that helps people who want more control over how they age, design a personalized plan for their health. Hone combines comprehensive biomarker testing, one-on-one physician consultations, and personalized treatment into an ongoing relationship that adapts as patients’ goals change. Treatment spans testosterone replacement therapy, menopause hormone therapy, weight management, peptides, thyroid, heart health, and sexual health. Care is powered by Hone’s proprietary AI clinical platform, Longevity OS, which gives physicians a real-time view of each patient’s health across specialties. With more than 200,000 patients treated, 750,000 tests administered, and 25 million health markers processed Hone has built one of the world’s largest repositories of hormone and metabolic data. That data feeds Longevity OS, sharpening its clinical intelligence with every patient Hone treats. For more information, visit www.honehealth.com | @hone.health

About MarcyPen Capital Partners

MarcyPen Capital Partners (“MarcyPen”) is a first-of-its-kind global investment platform that provides strategic capital to growth-stage consumer businesses that create, move, and lead culture. Founded by builders of some of the most iconic brands of our time, the firm provides solutions-oriented capital to leading consumer businesses positioned to meet the needs and expectations of the everchanging consumer, prioritizing strong engagement and collaboration with the companies it invests in. MarcyPen’s trusted formula combines a business-building playbook with a highly influential global ecosystem of partners, operators, and leaders. The firm pursues investments globally across subsectors that include beauty & personal care, consumer products, fashion & lifestyle, food & beverage, health & wellness, marketplaces, PR & creative, and tech-enabled services.

About Kinship Ventures

Kinship Ventures is a multi-stage venture investment platform founded by Gwyneth Paltrow and Moj Mahdara, backing high-agency founders who invent new markets and build enduring companies that define the next era. Kinship invests from early conviction through scale across frontier technology, AI, health, longevity, women’s health, and next-generation consumer. Built by founders and operators, Kinship brings more than capital — combining hands-on operating experience with strategic access, distribution, cultural intelligence, and a deeply connected ecosystem to help founders anticipate what’s next, navigate pivotal moments, and build for the long term. Learn more at kinshipventures.co.

SOURCE Hone Health

Sequel.io Raises $15M to Build a New Category in Video-Driven Audience Intelligence

Sorenson Capital-led funding will accelerate AI-powered activation of first-party video and website engagement data, connecting human interactions with intelligent go-to-market strategies.

Quick Facts:

  • Funding: Sequel.io has raised $15 million in a round led by Sorenson Capital.
  • Differentiation: Sequel combines webinar engagement with website behavior at the contact and account level, creating a unique source of first-party intelligence into buyer interests and intent.
  • Human-led, AI-scaled: Sequel uses the intelligence taken from human interactions to power AI agents that help marketers personalize experiences, create content and drive more relevant buyer engagement across go-to-market (GTM).
  • Customer Proof: Customers include ElevenLabs, Profound, Datadog and Clay. ElevenLabs generated $14 million in direct pipeline and influenced more than $85 million in pipeline in six months using Sequel.

SAN FRANCISCO, Nov. 18, 2026 — Sequel.io, a video-driven audience intelligence and activation platform, today announced $15 million in funding led by Sorenson Capital, bringing total funding to approximately $26 million. New investors in the round include High Alpha, Album VC and Webflow Ventures, with additional participation from existing investors Javelin Venture Partners, Struck Capital, Alumni Ventures and Social Leverage. The investment will support product innovation and enterprise growth as Sequel helps marketers turn human video engagement and website behavior into unique first-party intelligence that AI agents can act on across GTM.

From Human Engagement to First-Party Audience Intelligence
Most platforms still treat webinars as a one-off event. The experience often lives off-site, separate from the rest of the buyer journey and the tools marketing teams use every day. That leaves teams doing more manual work to run programs and makes it harder to carry what they learn from the event into the rest of GTM.

Sequel takes a different approach. Its video is hosted directly on a brand’s website and connects what people watch, ask and respond to during live, simulive and on-demand video with the other content they explore across the site. It’s the only provider in its category combining these signals at both the individual contact and account level. This gives marketers a clearer view of audience interests, emerging purchase intent and engagement across buying groups, and the context to make outreach and experiences more relevant.

“Video on its own can’t build buyer trust at scale, and AI on its own can’t create the context brands need to grow pipeline,” said Oana Manolache, co-founder and CEO of Sequel.io. “The opportunity is in bringing human conversation, first-party audience intelligence and AI agents together. That gives brands a better way to understand buyers, build trust and turn those relationships into growth. This funding gives us the opportunity to push that vision further and help shape what modern go-to-market looks like in the AI era.”

As AI-generated communication becomes more common, Sequel sees human-led video as a way for brands to build trust while learning what audiences actually care about. Its AI agents can use that first-party context to inform program planning, content creation, personalization and follow-up. The platform can personalize website experiences, publish video summaries and recaps to landing pages, and make original expertise discoverable by future visitors, search engines and AI answer engines. Customers can also build custom agents within Sequel or connect through its MCP server.

“The next era of go-to-market will be won by the companies that understand their buyers best, and that understanding starts with first-party data,” said Eric Hilton, partner at Sorenson Capital. “AI agents are only as good as the data they act on, and few signals are richer than the first-party data around how a real buyer engages with a company’s video and website. Sequel owns that moment, and we believe it’s well positioned to define this emerging category.”

Customer Momentum and Measurable Results
Sequel customers include ElevenLabs, Clay, Carta, Extreme Networks, Morningstar DBRS, Cato Networks, MaintainX and symplr. The company has grown revenue 3x for three consecutive years, now serves 6 million users globally and has grown its enterprise customer base 5x since January 2026. Sequel’s net revenue retention is rising significantly, as customers renew and expand their usage on the platform.

The funding will help Sequel expand its enterprise business and develop more ways to activate audience intelligence across the customer journey, including personalized website experiences, reusable video content and custom agent workflows.

“Sequel makes interactive video native to a brand’s domain, turning passive web pages into high-intent conversion engines,” said Dan Brown, head of Webflow Ventures. “As an agentic web marketing platform, Webflow helps marketing teams turn their websites into their most valuable growth channel, and Sequel brings that same belief to video.”

Customer Results

  • ElevenLabs used Sequel to generate $14 million in direct pipeline and influence more than $85 million in pipeline, against an initial webinar pipeline target of $100,000 in just six months.
    • “Sequel has been a great partner in helping us scale up our webinar program,” said Luke Harries, growth at ElevenLabs. 
  • Apollo.io used Sequel.io to embed product webinars directly inside its platform, helping drive a 500% increase in product adoption and six times more user meetings booked.
  • 6sense used Sequel.io to power its ABM-driven “Level Up” webinar series, generating more than 8,600 registrations and millions of dollars in influenced pipeline.
  • Carta used Sequel.io to turn webinars into a recurring revenue channel, generating more than 51,000 registrations and millions in ARR each year.

About Sequel.io
Sequel helps B2B marketing teams run live and on-demand video directly on their own websites, connect video engagement with first-party website behavior and use that context to create better content, more relevant experiences and more opportunities for growth.

By connecting human video, first-party audience context and AI agents, Sequel helps marketers turn webinars and video into a go-to-market engine.

The future of GTM is more human than you think.

Media Contact
PANBlast for Sequel.io
[email protected]

SOURCE Sequel.io

LODAS Markets and Variant Investments Partner to Bring Competitive Secondary Liquidity to Evergreen Fund Investors

Offers expanded liquidity opportunities for Variant Alternative Income Fund (NICHX) shareholders, following successful LODAS/Harrison Street auctions

OVERLAND PARK, Kan. and PORTLAND, Ore., Nov. 18, 2026 — LODAS Markets, Inc. (“LODAS”), operator of a leading secondary marketplace for alternative investments, and Variant Investments, an alternative private credit investment manager, today announced plans to launch interval fund auctions for the Variant Alternative Income Fund (NICHX) beginning in January 2027.

The announcement is a culmination of ongoing discussions for the last several quarters between the two parties as an option to potentially generate liquidity for shareholders. The first Variant auction is expected to launch in January with specific dates, eligible share classes and pricing parameters to be announced. The auctions will complement the fund’s existing quarterly repurchase program, which will remain unchanged.

  • The planned auctions build upon LODAS’s successful Harrison Street interval fund auctions in September-October 2026 and represent another step toward making competitive secondary liquidity more accessible across the growing evergreen fund market.
  • The initiative will provide eligible Variant shareholders with an additional avenue to seek liquidity beyond the fund’s existing quarterly repurchase program. Unlike fixed-price tender offers, LODAS auctions bring multiple buyers and sellers together in a competitive space, allowing demand to drive price discovery and creating opportunities for more favorable execution prices.
  • The auction process enables multiple parties to compete, providing shareholders with an alternative approach to price discovery, rather than relying on a single buyer to determine the price.

LODAS Founder and CEO Brian King said, “We believe every alternative investment deserves a transparent, competitive market where buyers and sellers determine the price. Variant shares our vision for a more modern approach to investor liquidity. Together, we’re demonstrating how fund managers can embrace secondary auctions to create greater choice, transparency and opportunity for their shareholders.”

Variant Co-Founder and Portfolio Manager JB Hayes said, “We welcome the opportunity for shareholders to access potential liquidity through the recent partnership with LODAS Markets. In addition to our standard quarterly redemptions, Variant is committed to finding innovative opportunities for shareholder liquidity that support the discovery of competitive pricing.”

LODAS’s inaugural Harrison Street auction demonstrated the potential of competitive price discovery, as approximately 91% of shares offered were successfully sold and 41% of shares sold achieved prices above their sellers’ original asking prices. The auction was completed September 23, 2026.

Mr. King said: “Secondary liquidity shouldn’t be an afterthought in alternative investments. As evergreen funds continue to grow, we believe competitive secondary options will become an increasingly important part of the industry’s infrastructure.”

Participation will be subject to applicable eligibility and transfer requirements. Execution and price improvement are not guaranteed.

About LODAS Markets
LODAS Markets is a financial technology company modernizing the alternative investment lifecycle through secondary-market liquidity solutions and automated transfer agent technology. Through its wholly owned subsidiary, LODAS Securities LLC, an SEC-registered broker-dealer and FINRA/SIPC member, LODAS operates a marketplace connecting buyers and sellers of alternative investments, including non-traded REITs, BDCs, interval funds and other private-market securities.

For more information, visit www.lodasmarkets.com.

About Variant Investments
Variant Investments, established in 2017 and based in Portland, Ore., is an SEC-registered alternative credit investment manager with $2.4 billion in assets under management. The firm’s strategies focus on uncorrelated income-generating assets in niche markets offered to investors primarily through institutional closed-end interval funds. For more information, visit www.variantinvestments.com.

Media Contacts 

For LODAS Markets
Randy Williams
917-213-5980
[email protected]

For Variant Investments
Margaret Kirch Cohen
Newton Park PR
847-507-2229
[email protected] 

Securities transactions are conducted through LODAS Securities LLC, member FINRA/SIPC. Secondary-market transactions may occur below a fund’s reported net asset value (NAV). There is no guarantee of liquidity, execution or price improvement.

Disclosures

The Variant Alternative Income Fund (the “Fund”) is a continuously-offered, non-diversified, registered closed-end fund with limited liquidity. There is no guarantee the Fund will achieve its objective. An investment in the Fund should only be made by investors who understand the risks involved, who are able to withstand the loss of the entire amount invested and who can bear the risks associated with the limited liquidity of Shares.

Important Risks: Given the substantial investment by the Funds in private securities, there is no reliable liquid market available for the purposes of valuing the majority of the Funds’ investments. There can be no guarantee that the basis of calculation of the value of the Funds’ investments used in the valuation process will reflect the actual value on realization of those investments. Shares are an illiquid investment. You should generally not expect to be able to sell your Shares (other than through the repurchase process), regardless of how the Fund performs. Although the Fund is required to implement a Share repurchase program, only a limited number of Shares will be eligible for repurchase by the Fund.

An investment in the Fund is speculative, involves substantial risks, including the risk that the entire amount invested may be lost, and should not constitute a complete investment program. The Fund may leverage its investments by borrowing, use of swap agreements, options or other derivative instruments. The Fund is a non-diversified management investment company, meaning it may be more susceptible to any single economic or regulatory occurrence than a diversified investment company. In addition, the Fund is subject to investment related risks of the underlying funds, general economic and market condition risk.

Alternative investments provide limited liquidity and include, among other things, the risks inherent in investing in securities, futures, commodities and derivatives, using leverage and engaging in short sales. The Fund’s investment performance depends, at least in part, on how its assets are allocated and reallocated among asset classes and strategies. Such allocation could result in the Fund holding asset classes or investments that perform poorly or underperform. Investments and investment transactions are subject to various counterparty risks. The counterparties to transactions in over-the-counter or “inter-dealer” markets are typically subject to lesser credit evaluation and regulatory oversight compared to members of “exchange-based” markets. This may increase the risk that a counterparty will not settle a transaction because of a credit or liquidity problem, thus causing the Fund to suffer losses.

Participation in any secondary-market transaction is voluntary. Shares may be sold at prices above or below the Fund’s net asset value (“NAV”), and there is no assurance that any sell order will be executed. Auction pricing and results may differ from prior auctions and are not indicative of future outcomes. Investors may incur commissions, transaction fees, or other expenses in connection with participation.

BEFORE INVESTING YOU SHOULD CAREFULLY CONSIDER THE FUND’S INVESTMENT OBJECTIVES, RISKS, CHARGES AND EXPENSES. THIS AND OTHER INFORMATION IS IN THE PROSPECTUS, A COPY OF WHICH MAY BE OBTAINED FROM (877) 770-7717 OR WWW.VARIANTINVESTMENTS.COM. PLEASE READ THE PROSPECTUS CAREFULLY BEFORE YOU INVEST.

Past performance is not indicative of future results

The Fund is distributed by Distribution Services, LLC. Variant Investments, LLC (the “Investment Manager”) serves as the investment manager of the Fund. Harrison Street’s closed-end interval funds are distributed by Foreside Funds Distributors, LLC, which is an affiliate of Distribution Services, LLC. Distribution Services, LLC and Foreside Funds Distributors, LLC are not affiliated with the Investment Manager or any other individual/entity referenced.

SOURCE LODAS Markets

Speakeasy Announces $18.8 Million Series A to Power the Growing IRL Economy

Led by VMG Technology, the round will accelerate Speakeasy’s unified operations, payments, and AI platform for live entertainment and hospitality

NEW YORK, Nov. 18, 2026 — Speakeasy, the infrastructure powering live experiences and the in-real-life (IRL) economy, today announced the completion of an oversubscribed $18.8 million Series A, bringing its total funding to approximately $27 million. The round was led by VMG Technology, with participation from Capital One Ventures, Positive Sum, and Yamaha Music Innovations Fund.

Founded in 2023 by Tamas An, Alex Manavi, and Paul Stacek, Speakeasy brings ticketing, payments, reservations, guest data, and direct marketing into a single platform for leading live experience brands and hospitality enterprises, including TAO Group Hospitality, Fontainebleau Development, E11EVEN, Barstool, Cipriani, Snow & Surf Lodge, Breakaway Music Festival, Resorts World, and Off Grid @ F1. Speakeasy now powers live experience operators across 45+ cities nationwide.

The financing comes at a time of consumers increasingly prioritizing experiences over purchasing goods. Between 2023 and 2025, the global experiences market grew more than three times that of nonessential goods categories, with projections showing global live music revenue growing by $28 billion between 2025 and 2035 at a 6% annual growth rate, underscoring the long-term opportunity for infrastructure that connects operations, commerce, and guest relationships.

“Live experiences have run on fragmented tools that never captured the full relationship between a guest and the event operator. We set out to fix this by consolidating the operating stack and putting clients and product first,” said Alex Manavi, Co-Founder and CEO of Speakeasy. “In an increasingly AI-driven world, we made an early bet that in-person experiences would become a scarce and premium good, and the businesses that create those moments deserve technology that is purpose-built for their operations. Our platform supports the guest relationship from the first booking through the visits and interactions that follow, so our partners can operate their business as efficiently as possible using AI-enabled tools that support the core workflows we help optimize. This round lets us double down on becoming the source of truth and the preeminent ecosystem for all things IRL, and we’re grateful to our investors who share that conviction.”

Speakeasy will use the new capital to deepen its core platform, accelerate AI capabilities, and continue to expand into new markets and categories. Its AI investment centers on embedding intelligence directly within and on top of its critical workflows where guest data is created, captured, and consolidated, enabling operators to generate more revenue, deliver more personalized experiences, and automate mundane processes. The company will also strengthen its partnerships division, integrations with enterprise systems, and expand consumer discovery and booking across its partner network.

“10% of households drive almost 50% of US consumer spending. For the business of hospitality or fandom, the stakes have never been higher: you have to truly know your customer. Not the fractured view, divided across legacy tools, but the entire guest relationship. Speakeasy is manifesting deep customer knowledge for the most sophisticated operators in the experience economy, and we are investing behind bringing that capability to the wider market,” said Indy Guha, General Partner of VMG Technology.

“We see Speakeasy’s potential as an operating system for live experiences, especially as they grow in importance to consumers,” said Nathan Krishnamurthy, partner, Capital One Ventures. “Speakeasy modernizes ticketing, reservations, guest management and operations and serves as an important payment partner. We are impressed with the team’s execution and through this investment, we look forward to supporting their continued growth in hospitality, sports, music and live entertainment.”

For more information about Speakeasy, visit spkeasy.com.

About Speakeasy

Speakeasy is the operating infrastructure powering live experiences and the in-real-life (IRL) economy. Its integrated platform brings together ticketing, payments, reservations, premium experiences, guest CRM, and direct marketing, with AI-driven capabilities that help venues, hospitality groups, festivals, and event organizers streamline operations, grow revenue, and deliver more personalized experiences. For more information, visit spkeasy.com.

SOURCE Speakeasy

Vero Security Raises $11M to Shape How AI Security Engineering is Done

Founded in 2025, Vero already counts multiple Fortune 500 companies among its customers. The round was led by TLV Partners, with participation from GTM Capital, Maple Capital and angel investors.

The organizational shift is already underway. Recent research from IANS and Artico Search found that 65% of companies with at least $10 billion in revenue had assigned someone to lead AI security, but only 18% had made it a dedicated role. At the rest of the organizations surveyed, it was added to an existing leader’s job. Whoever holds it faces a moving target. Employees adopt new AI tools and agents, connect them to enterprise systems and grant them permissions to access sensitive data and take actions. At the same time, AI vendors continuously introduce new capabilities, models, plugins and integrations that can change the security implications of existing configurations.

“CISOs have seen enough dashboards and tables that tell their teams what’s wrong and leave the work to them. AI Security Engineering deserves a better operating model, designed for AI rather than borrowed from other areas of security,” said Elad Tessler, Co-Founder and CEO of Vero Security. “We’re working alongside the first generation of AI security leaders and building Vero around what they actually need: a platform that does the work, keeps protections current as AI changes, and brings them only the decisions that require human judgment.”

A new discipline needs more than new technology. The professionals taking on AI security are defining the role as they go, with few established playbooks or formal training paths. To help build that foundation, Vero is launching AISecurityEngineering.org, an open community and knowledge center featuring practical field guides, workshops and the ASE credential track.

At the core of Vero’s platform is its AI Runtime Governor, designed to put security decisions into effect as AI operates. Its runtime controls inspect supported prompts, tool calls and agent actions, enforcing approved policies at the moment an action is attempted. Vero can stop a coding agent from reading secrets it has no reason to touch, block agent actions that violate security policies and keep malicious skills or prompt injection from triggering unauthorized behavior.

These protections are applied during execution, without waiting for manual security review.

Vero works through the endpoint, identity, AI and security tools a company already runs, so employees have nothing new to install. It combines continuous discovery with its own security analysis and runtime enforcement, maintaining visibility into AI tools, agents, connected systems, configurations and permissions, and giving security professionals the context to understand risks and define effective protections.

The platform also carries security decisions through to execution. Security teams establish policies and determine which changes Vero can handle automatically. Vero implements approved controls, coordinates remediation with relevant owners, verifies completion and keeps protections aligned as the environment evolves. When a change requires a new risk decision, Vero brings the analysis and recommended action to the responsible security professional.

One decision from the security team can mean dozens of controls behind the scenes. A new Fortune 1000 customer, for example, began its Vero deployment with a simple policy: only developers could connect AI agents to corporate code repositories or allow them to execute code. Within minutes, Vero translated that single decision into more than 15 security controls across coding agents, MCP servers, skills, identities and runtime actions, automatically putting them into effect across the organization. As AI tools and capabilities evolve, Vero continuously adjusts those controls to keep the original policy enforced.

“AI Security Engineering is becoming a core responsibility inside enterprise security organizations,” said Rona Segev, Co-Founder & Managing Partner at TLV Partners, which led the round. “The professionals taking on that responsibility need technology designed for the pace and complexity of AI. Vero is bringing security expertise, continuous execution and runtime enforcement together in a platform built for how this new discipline needs to operate.”

GTM Capital invested following a structured evaluation with its community of Fortune 500 CIOs and CISOs, who worked directly with Vero before the firm committed.

“AI is becoming a new attack surface in the enterprise, and we’re hearing directly from CISOs how quickly AI Security Engineering is becoming a distinct responsibility,” said Saqib Awan, Founder and Managing Director at GTM Capital. “We evaluated dozens of companies in this space. Vero stood out because it’s building technology that helps security professionals do the work, from understanding risks to enforcing protections. It’s GTM Capital’s first investment in an Israeli-founded cybersecurity company since Cyera.”

Vero was founded by Elad Tessler (CEO) and Daniel Meirov (CTO). Tessler previously led product at Astrix Security, acquired by Cisco in 2026. Meirov was the first employee at Sightfull, where he led R&D and product. The two met in Unit 8200, where they co-led a cyber operations unit of more than 100 people.

The company will use the funding to advance its AI Security Engineering platform, expand coverage across enterprise AI technologies and security workflows, and grow its go-to-market presence in the United States.

About Vero Security

Vero Security is building the platform for AI Security Engineering. Its AI Runtime Governor provides security professionals with purpose-built technology for continuously discovering, assessing and securing enterprise AI. Combining security expertise, automated execution and runtime enforcement, Vero helps the people responsible for AI security maintain effective protections as AI tools, agents and permissions evolve. Founded in 2025, Vero is backed by TLV Partners, GTM Capital and Maple Capital, with offices in New York and Tel Aviv.

Learn more at vero.security.

Media Contact
[email protected]

SOURCE Vero Security

Isomorphic Labs anuncia una ronda de financiación de serie C de 5.000 millones de dólares

Greenoaks y Sequoia Capital lideran conjuntamente esta ronda que ha superado la demanda prevista, mientras Isomorphic Labs continúa avanzando en sus modelos de simulación fundamentales, desarrollando y ampliando su cartera de candidatos a fármacos (tanto propios como en colaboración) y construyendo su infraestructura global de bioingeniería impulsada por inteligencia artificial.

LONDRES, 17 de noviembre de 2026 — Isomorphic Labs, una empresa de inteligencia artificial centrada en el diseño y desarrollo de nuevos medicamentos, ha anunciado hoy una ronda de financiación de serie C por valor de 5.000 millones de dólares. La ronda estuvo coliderada por Greenoaks y Sequoia Capital, junto con Andreessen Horowitz (a16z) y otros nuevos inversores, contando además con una importante inversión continuada por parte de Alphabet. En la ronda también participaron todos los inversores actuales: Thrive Capital, MGX, GV, CapitalG, Temasek y el UK Sovereign AI Fund.

Isomorphic está ampliando su motor patentado de diseño de fármacos (IsoDDE) y su cartera de candidatos terapéuticos desarrollada mediante inteligencia artificial con el fin de ofrecer la próxima generación de medicamentos. IsoDDE integra un conjunto de modelos fundamentales de IA basados en simulación, diseñados para operar de forma nativa en diversas áreas terapéuticas y modalidades farmacológicas. IsoDDE explora amplios espacios químicos y permite al equipo de primer nivel de Isomorphic diseñar, perfeccionar y crear moléculas meticulosamente concebidas que poseen propiedades óptimas, características de los fármacos eficaces.

La amplitud y precisión de los modelos de simulación que conforman IsoDDE elevan la exactitud de las predicciones a niveles cercanos a los resultados experimentales, proporcionando un conjunto de capacidades que impulsan el desarrollo de medicamentos innovadores. Estos modelos, junto con potentes agentes patentados capaces de analizar y razonar sobre sistemas biológicos de gran complejidad, se traducen de manera directa y constante en avances dentro de la cartera de candidatos terapéuticos de la empresa, que abarca múltiples modalidades, abordando algunos de los desafíos más complejos del sector. Este impulso está generando resultados preclínicos positivos, tanto en programas internos centrados en oncología e inmunología como en proyectos desarrollados con socios, sentando así las bases para el inicio de la fase clínica.

Este nuevo capital acelera los avances científicos y los progresos en inteligencia artificial (IA) propios de la empresa que está logrando Isomorphic. La compañía seguirá perfeccionando IsoDDE y profundizando en nuevas áreas de la biología mediante el uso de modelos altamente avanzados. Con el fin de desarrollar clases de terapias nuevas y transformadoras, Isomorphic está creando un ecosistema de socios que permita avanzar en la comprensión de los mecanismos biológicos de las enfermedades. Paralelamente, la empresa está construyendo la infraestructura global necesaria para impulsar el futuro de la bioingeniería basada en la IA. Los fondos también servirán para seguir desarrollando una infraestructura escalable centrada en la IA destinada al desarrollo traslacional y clínico, a medida que la compañía avanza con sus fármacos candidatos hacia los ensayos clínicos.

“Cuando fundamos Isomorphic, estábamos convencidos de que la biología podía comprenderse y modelarse a su nivel molecular más fundamental, y que este proceso podía acelerarse radicalmente mediante la IA”, afirmó Sir Demis Hassabis, fundador y consejero delegado de Isomorphic Labs. “Nuestro motor de diseño de fármacos genera moléculas con una precisión y una velocidad sin precedentes. Esta ronda de financiación nos permite acelerar nuestros avances: desarrollar modelos biológicos fundamentales, profundizar en nuestra comprensión sistémica de las enfermedades e impulsar nuestros primeros programas terapéuticos hacia los ensayos clínicos, con el objetivo de generar un impacto tangible para los pacientes”.

“Cada semana logramos avances científicos reproducibles gracias a nuestros modelos”, afirmó Max Jaderberg, presidente de Isomorphic Labs. “Estos avances se traducen directamente en mejores perfiles moleculares con potencial para convertirse en nuevos medicamentos, permitiendo abordar algunos de los desafíos más complejos en el descubrimiento de fármacos. Nuestros equipos interdisciplinarios combinan a investigadores líderes a nivel mundial en aprendizaje automático con expertos de primer nivel en la búsqueda de fármacos; juntos, resuelven de forma habitual problemas biológicos complejos que habían estancado la investigación tradicional durante décadas. Estamos transformando nuestros descubrimientos en posibles medicamentos que pueden cambiar vidas, apoyándonos en la infraestructura que estamos creando para el futuro de la bioingeniería, gracias al respaldo de nuestros inversores”.

“El descubrimiento y desarrollo de nuevos medicamentos es un desafío de optimización de una escala casi infinita”, señaló Neil Mehta, fundador y socio director de Greenoaks. “Isomorphic está transformando este proceso mediante la creación de sistemas de aprendizaje profundo capaces de predecir comportamientos biológicos complejos con una precisión extraordinaria, trazando así, de manera sistemática, el camino hacia nuevos fármacos. Estamos convencidos de que Demis, Max y el equipo de Isomorphic están construyendo el futuro del descubrimiento de medicamentos impulsado por la inteligencia artificial, y nos enorgullece colaborar con ellos en esta misión fundamental”.

“Isomorphic Labs está desarrollando tecnología fundamental para el futuro de la medicina”, comentó Konstantine Buhler, socio de Sequoia Capital. “Resulta inspirador ver cómo el equipo de Isomorphic transforma la inteligencia artificial avanzada en una cartera creciente de fármacos candidatos. Utilizar la IA para mejorar la salud humana es uno de los retos más importantes de nuestra generación. Nos sentimos orgullosos de coliderar esta ronda de financiación y de contribuir al avance del descubrimiento científico en el ámbito de la medicina”.

ACERCA DE ISOMORPHIC LABS

Isomorphic Labs se fundó en 2021 con el objetivo de transformar el descubrimiento de fármacos mediante la inteligencia artificial, dando paso a una nueva era de avances biomédicos. Isomorphic Labs está dirigida por el consejero delegado Sir Demis Hassabis y el presidente Max Jaderberg. Isomorphic Labs ha desarrollado un motor de diseño de fármacos basado en IA líder a nivel mundial, que comprende modelos fundamentales de IA capaces de operar en múltiples áreas terapéuticas y modalidades farmacológicas. La compañía innova continuamente en la arquitectura de modelos y desarrolla capacidades de vanguardia para impulsar el diseño de fármacos. Isomorphic Labs tiene su sede en Londres y oficinas en Cambridge, Massachusetts y Lausana, Suiza. Isomorphic Labs está impulsando una amplia y ambiciosa cartera de diseño de fármacos a través de programas en colaboración y programas internos propios. Para obtener más información, visite www.isomorphiclabs.com y síganos en LinkedIn y X.

Isomorphic Labs gibt eine Serie-C-Finanzierungsrunde in Höhe von 5 Milliarden US-Dollar bekannt

Greenoaks und Sequoia Capital leiten gemeinsam die überzeichnete Finanzierungsrunde, während Isomorphic Labs weiterhin seine grundlegenden Simulationsmodelle vorantreibt, seine Pipeline an internen und in Partnerschaft entwickelten Medikamentenkandidaten ausbaut und skaliert sowie seine globale, KI-gesteuerte Bioengineering-Infrastruktur aufbaut.

LONDON, 17. November 2026 — Isomorphic Labs, ein KI-Unternehmen, das sich auf die Konzeption und Entwicklung neuer Medikamente konzentriert, gab heute eine Serie-C-Finanzierungsrunde in Höhe von 5 Milliarden US-Dollar bekannt. Die Runde wurde gemeinsam von Greenoaks und Sequoia Capital geleitet, zusammen mit Andreessen Horowitz (a16z) und mehreren anderen neuen Investoren, wobei Alphabet weiterhin erheblich investierte. An der Runde beteiligten sich zudem alle bestehenden Investoren: Thrive Capital, MGX, GV, CapitalG, Temasek und der britische Sovereign AI Fund.

Isomorphic baut seine firmeneigene Wirkstoffdesign-Engine (IsoDDE) und seine mit KI entwickelte Pipeline an therapeutischen Kandidaten aus, um die nächste Generation von Medikamenten auf den Markt zu bringen. IsoDDE vereint eine Reihe grundlegender Simulations-KI-Modelle, die von Haus aus in mehreren Therapiebereichen und Wirkstoffklassen einsetzbar sind. IsoDDE erkundet riesige chemische Räume, um es dem Weltklasse-Team von Isomorphic zu ermöglichen, präzise konstruierte Moleküle mit optimalen arzneimittelähnlichen Eigenschaften zu entwerfen, zu verfeinern und bereitzustellen.

Die Bandbreite und Präzision der Simulationsmodelle innerhalb von IsoDDE lassen die Vorhersagen an die Genauigkeit experimenteller Ergebnisse heranreichen und bieten eine Reihe von Möglichkeiten zur Weiterentwicklung innovativer Medikamente. In Kombination mit leistungsstarken, firmeneigenen Algorithmen, die hochkomplexe biologische Systeme durchlaufen und analysieren, führen diese Modelle direkt und wiederholt zu Fortschritten in der multimodalen Pipeline therapeutischer Wirkstoffkandidaten des Unternehmens und lösen damit einige der schwierigsten Probleme der Branche. Diese Dynamik führt zu positiven präklinischen Ergebnissen, sowohl bei internen Programmen in den Bereichen Onkologie und Immunologie als auch bei Projekten mit Partnern, und ebnet den Weg für den Eintritt in die klinische Phase.

Dieses neue Kapital beschleunigt die wissenschaftlichen Durchbrüche und die firmeneigenen Fortschritte im Bereich der KI, die Isomorphic erzielt. Das Unternehmen wird IsoDDE weiter ausreifen lassen und mit hochentwickelten Modellen tiefer in neue Bereiche der Biologie vordringen. Um neue und bahnbrechende Klassen von Therapeutika auf den Markt zu bringen, baut Isomorphic ein Partner-Ökosystem auf, um das Verständnis der mechanistischen Krankheitsbiologie voranzutreiben. Parallel dazu errichtet das Unternehmen die globale Infrastruktur, die erforderlich ist, um die Zukunft der KI-gesteuerten Bioingenieurwissenschaften voranzutreiben. Die Erlöse werden zudem den weiteren Aufbau einer skalierbaren, KI-orientierten Infrastruktur für die translationale und klinische Entwicklung unterstützen, während das Unternehmen seine Wirkstoffkandidaten in klinische Studien überführt. 

„Als wir Isomorphic gründeten, waren wir davon überzeugt, dass Biologie auf der grundlegendsten molekularen Ebene verstanden und modelliert sowie durch KI radikal beschleunigt werden kann”, sagte Sir Demis Hassabis, Gründer und CEO von Isomorphic Labs. „Unsere Engine für das Wirkstoffdesign generiert Moleküle mit beispielloser Präzision und Geschwindigkeit. Diese Finanzierungsrunde ermöglicht es uns, unsere Fortschritte zu beschleunigen: grundlegende biologische Modelle zu entwickeln, unser systemisches Verständnis von Krankheiten zu vertiefen und unsere ersten therapeutischen Programme in Richtung klinischer Studien voranzutreiben, um greifbare Ergebnisse für Patienten zu erzielen.”

„Jede Woche erzielen wir dank unserer Modelle wiederholbare wissenschaftliche Fortschritte”, sagte Max Jaderberg, Präsident von Isomorphic Labs.„Diese führen direkt zu besseren molekularen Profilen, die das Potenzial haben, neue Medikamente zu werden und einige der schwierigsten Probleme in der Wirkstoffforschung zu lösen. Unsere interdisziplinären Teams vereinen weltweit führende Forscher im Bereich des maschinellen Lernens mit erstklassigen Wirkstoffforschern, und gemeinsam lösen sie regelmäßig komplexe biologische Probleme, an denen die traditionelle Forschung seit Jahrzehnten feststeckt. Wir setzen unsere Entdeckungen direkt in potenzielle, lebensverändernde Medikamente um – aufbauend auf der Infrastruktur, die wir mit dieser Investorenunterstützung für die Zukunft der Bioingenieurwissenschaften aufbauen.”

„Die Entdeckung und Entwicklung neuer Medikamente ist eine Optimierungsherausforderung von nahezu unendlichem Ausmaß”, sagte Neil Mehta, Gründer und geschäftsführender Gesellschafter von Greenoaks.„Isomorphic verändert diesen Weg grundlegend, indem es Deep-Learning-Systeme entwickelt, die komplexe biologische Verhaltensweisen mit bemerkenswerter Genauigkeit vorhersagen und den Weg zu neuen Medikamenten systematisch aufzeigen können. Wir sind überzeugt, dass Demis, Max und das Isomorphic-Team die Zukunft der KI-gestützten Wirkstoffforschung gestalten, und wir sind stolz darauf, sie bei dieser wichtigen Mission zu unterstützen.”

„Isomorphic Labs entwickelt grundlegende Technologien für die Zukunft der Medizin”, sagte Konstantine Buhler, Partner bei Sequoia Capital. „Es ist inspirierend zu sehen, wie das Isomorphic-Team fortschrittliche KI in ein wachsendes Portfolio an Wirkstoffkandidaten umsetzt. Der Einsatz von KI zur Verbesserung der menschlichen Gesundheit ist eine der wichtigsten Herausforderungen unserer Generation. Wir sind stolz darauf, diese Finanzierungsrunde mit anzuführen und dazu beizutragen, wissenschaftliche Entdeckungen in der Medizin voranzutreiben.”

INFORMATIONEN ZU ISOMORPHIC LABS

Isomorphic Labs wurde 2021 gegründet, um die Arzneimittelforschung mit Hilfe künstlicher Intelligenz zu revolutionieren und damit eine neue Ära biomedizinischer Durchbrüche einzuläuten. Isomorphic Labs wird von CEO Sir Demis Hassabis und Präsident Max Jaderberg geleitet. Isomorphic Labs hat eine weltweit führende KI-Engine für das Wirkstoffdesign entwickelt, die aus grundlegenden KI-Modellen besteht, die in der Lage sind, über mehrere Therapiebereiche und Wirkstoffklassen hinweg zu arbeiten. Das Unternehmen arbeitet kontinuierlich an Innovationen im Bereich der Modellarchitektur und entwickelt modernste Funktionen, um das Wirkstoffdesign voranzutreiben. Isomorphic Labs hat seinen Hauptsitz in London und verfügt über Niederlassungen in Cambridge, Massachusetts, sowie in Lausanne, Schweiz. Isomorphic Labs treibt ein breit gefächertes und ehrgeiziges Portfolio im Bereich des Wirkstoffdesigns durch Partnerschaftsprogramme und eigene, vollständig unternehmenseigene Programme voran. Weitere Informationen finden Sie unter www.isomorphiclabs.com und folgen Sie uns auf LinkedIn und X.

Isomorphic Labs annonce une levée de fonds de série C de 5 milliards de dollars

Greenoaks et Sequoia Capital ont conjointement mené ce tour de table sursouscrit, tandis qu’Isomorphic Labs poursuit le développement de ses modèles de simulation fondateurs, l’expansion et la croissance de son portefeuille de candidats médicaments internes et partenaires, ainsi que la construction de son infrastructure mondiale de bio-ingénierie basée sur l’IA.

LONDRES, 17 novembre 2026 — Isomorphic Labs, une société d’IA axée sur la conception et le développement de nouveaux médicaments, a annoncé aujourd’hui un tour de financement de série C de 5 milliards de dollars. Le tour de table a été mené conjointement par Greenoaks et Sequoia Capital, aux côtés d’Andreessen Horowitz (a16z) et de plusieurs autres nouveaux investisseurs, avec un investissement significatif continu de la part d’Alphabet. Ce tour de table a également bénéficié de la participation de tous les investisseurs existants : Thrive Capital, MGX, GV, CapitalG, Temasek et le Fonds souverain britannique pour l’IA.

Isomorphic développe son moteur de conception de médicaments propriétaire (IsoDDE) et son portefeuille de candidats thérapeutiques conçus avec l’IA pour produire la prochaine génération de médicaments. IsoDDE unifie une suite de modèles d’IA de simulation fondateurs qui fonctionnent nativement dans de multiples domaines thérapeutiques et modalités médicamenteuses. IsoDDE explore de vastes espaces chimiques pour permettre à l’équipe de classe mondiale d’Isomorphic de concevoir, d’affiner et de produire des molécules d’une ingénierie de qualité exceptionnelle dotées de propriétés optimales de type médicament.

L’étendue et la précision des modèles de simulation d’IsoDDE permettent d’approcher les prédictions avec une précision expérimentale et offrent un ensemble de fonctionnalités pour faire progresser les médicaments innovants. Associés à de puissants agents propriétaires capables de naviguer et de raisonner sur des systèmes biologiques très complexes, ces modèles se traduisent directement et de manière répétée par des progrès dans l’ensemble du portefeuille multimodal de candidats thérapeutiques de l’entreprise, s’attaquant ainsi à certains des problèmes les plus difficiles du secteur. Cette dynamique produit des résultats précliniques positifs, tant pour les programmes internes en oncologie et en immunologie qu’avec les partenaires, ouvrant la voie à l’entrée en phase clinique.

Ce nouveau capital accélère les percées scientifiques et les avancées en matière d’IA propriétaire réalisées par Isomorphic. L’entreprise continuera à développer l’IsoDDE et à explorer plus en profondeur de nouvelles pistes en biologie grâce à des modèles très avancés. Pour proposer de nouvelles classes de thérapies transformatrices, Isomorphic crée un écosystème de partenaires afin de faire progresser la compréhension de la biologie mécanistique des maladies. En parallèle, l’entreprise met en place l’infrastructure mondiale nécessaire pour alimenter l’avenir du génie biologique piloté par l’IA. Les fonds recueillis serviront également à soutenir la poursuite par l’entreprise du développement d’une infrastructure translationnelle et clinique évolutive axée sur l’IA, à mesure qu’elle fait progresser ses candidats médicaments vers les essais cliniques. 

« Lorsque nous avons fondé Isomorphic, nous étions convaincus que la biologie pouvait être comprise et modélisée au niveau moléculaire le plus fondamental et radicalement accélérée grâce à l’IA », a déclaré Sir Demis Hassabis, fondateur et PDG d’Isomorphic Labs. « Notre moteur de conception de médicaments génère des molécules avec une précision et une rapidité sans précédent. Ce tour de table nous permet d’accélérer nos progrès : élaborer des modèles biologiques fondamentaux, approfondir notre compréhension des maladies systémiques et mener nos premiers programmes thérapeutiques vers des essais cliniques afin d’avoir un impact concret pour les patients. »

« Chaque semaine, nous réalisons des progrès scientifiques reproductibles grâce à nos modèles », a déclaré Max Jaderberg, président d’Isomorphic Labs. « Ces éléments se traduisent directement par de meilleurs profils moléculaires susceptibles de donner naissance à de nouveaux médicaments et de résoudre certains des problèmes les plus difficiles de la découverte de médicaments. Nos équipes interdisciplinaires associent des chercheurs de renommée mondiale en apprentissage automatique à des spécialistes de la découverte de médicaments de haut niveau, et ensemble, ils résolvent régulièrement des problèmes biologiques complexes qui ont bloqué la recherche traditionnelle pendant des décennies. Nous traduisons directement nos découvertes en médicaments potentiellement révolutionnaires, grâce à l’infrastructure que nous mettons en place pour l’avenir du génie biologique avec le soutien de ces investisseurs. »

« Découvrir et développer de nouveaux médicaments est un défi d’optimisation d’une ampleur quasi infinie », a déclaré Neil Mehta, fondateur et associé directeur de Greenoaks. « Isomorphic transforme ce parcours, en construisant des systèmes d’apprentissage profond capables de prédire des comportements biologiques complexes avec une précision remarquable et de cartographier systématiquement le chemin vers de nouveaux médicaments. Nous pensons que Demis, Max et l’équipe d’Isomorphic sont en train de construire l’avenir de la découverte de médicaments guidée par l’IA et nous sommes fiers de nous associer à eux dans cette mission essentielle. »

« Isomorphic Labs construit une technologie fondamentale pour l’avenir de la médecine », a déclaré Konstantine Buhler, associé chez Sequoia Capital. « Il est inspirant de voir l’équipe d’Isomorphic traduire l’IA avancée en un portefeuille croissant de candidats médicaments. L’utilisation de l’IA pour améliorer la santé humaine est l’un des défis les plus importants de notre génération. Nous sommes fiers de codiriger ce cycle de financement et de contribuer à faire progresser la découverte scientifique en médecine. »

À PROPOS D’ISOMORPHIC LABS

Isomorphic Labs a été fondée en 2021 pour transformer la découverte de médicaments grâce à la puissance de l’intelligence artificielle, inaugurant ainsi une nouvelle ère de percées biomédicales. Isomorphic Labs est dirigée par son PDG, Sir Demis Hassabis, et son président, Max Jaderberg. Isomorphic Labs a mis au point un moteur de conception de médicaments IA de pointe, comprenant des modèles d’IA fondateurs capables de fonctionner dans de multiples domaines thérapeutiques et modalités médicamenteuses. L’entreprise innove constamment en matière d’architecture de modèles et développe des capacités de pointe pour faire progresser la conception de médicaments. Isomorphic Labs a son siège social à Londres et possède des bureaux à Cambridge (Massachusetts) et à Lausanne (Suisse). Isomorphic Labs développe un portefeuille de conception de médicaments vaste et ambitieux grâce à des programmes menés en partenariat et à des programmes internes détenus à 100 % par l’entreprise. Pour plus d’informations, rendez-vous sur www.isomorphiclabs.com et suivez-nous sur LinkedIn et X.